Molecular Formula | C17H12N2O |
Molar Mass | 260.29 |
Density | 1.237±0.06 g/cm3(Predicted) |
Boling Point | 464.4±45.0 °C(Predicted) |
Solubility | DMSO: 25.2 mg/mL |
Appearance | powder |
Color | white to beige |
pKa | 3.11±0.61(Predicted) |
Storage Condition | Sealed in dry,2-8°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
In vitro study | PFK15 is capable of producing potent growth inhibition in a range of cancer cells. PFK15 also reduced F26BP, glucose uptake, and intracellular ATP levels in Jurkat T-cell leukemia cells and H522 lung adenocarcinoma cells. |
In vivo study | In vivo, PFK15 has appropriate pharmacokinetic properties. PFK15 (25 mg/kg, I. P.) inhibits the growth, metastatic spread and glucose metabolism of LLC tumors in homologous mice. In three human xenografted athymic cancer mouse models, PFK15 also produced anticancer effects similar to those of certified chemotherapeutic drugs. |
Hazard Symbols | Xi - Irritant![]() |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.842 ml | 19.209 ml | 38.419 ml |
5 mM | 0.768 ml | 3.842 ml | 7.684 ml |
10 mM | 0.384 ml | 1.921 ml | 3.842 ml |
5 mM | 0.077 ml | 0.384 ml | 0.768 ml |